LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

Authors: Markus Moehler, Kohei Shitara, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli, T. Liu, Michael Schenker, Patricio Yañez, Mustapha Tehfé, Valerie Poulart, Dana Cullen, Ming Lei, Kaoru Kondo, M. Li, Jaffer A. Ajani, Yelena Y. Janjigian - Annals of Oncology 2020 cited by 205